ABSTRACT
PURPOSE: The condition of pituitary apoplexia contains the clinical spectre from life-threatening emergency to asymptomatic self-limiting course, which partly determines diagnostic delay and management. Outcome evaluation of course and management of pituitary apoplexia is hampered by the diverse presentation of this condition and requires appraisal. This study aimed to describe the patient journey, clinical presentation, and management of various types of pituitary apoplexy in a new classification to facilitate future outcome evaluation and identify unmet needs in the care process. METHODS: A single-center retrospective patient chart study was conducted between 2005-2021 (N = 98). Outcome measures were clinical symptoms at first presentation in hospital, being headache, consciousness, visual acuity, visual field defects (VFD), ophthalmoplegia, nausea, vomiting, fever, and hypopituitarism and care process characteristics. RESULTS: Mean age was 47.6 ± 16.6 years (51.0% male). We describe their patient journey and identified three different types, differing in clinical presentation, in-hospital route, and final treatment, e.g., Acute (type A, 52%), Subacute (type B, 22.5%), and Non-acute (type C, 25.5%). Type A generally presents with acute onset headaches, VFD, or ophthalmoplegia emergency setting, with lowest mean visual acuity of both eyes and frequent hypocortisolism. CONCLUSIONS: Pituitary apoplexy can be approached as a spectrum of disease with 3 main subtypes, with a different initial presentation, different in-hospital route resulting in different management. Acknowledging subtypes with particular needs for (emergency) referrals to Pituitary Tumors Center of Excellence (PTCOE) will serve patient care improvements, outcome evaluations and address areas for improvement.
Subject(s)
Ophthalmoplegia , Pituitary Apoplexy , Pituitary Neoplasms , Adult , Delayed Diagnosis , Female , Headache/diagnosis , Headache/etiology , Humans , Male , Middle Aged , Pituitary Apoplexy/diagnostic imaging , Pituitary Apoplexy/therapy , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/diagnostic imaging , Retrospective Studies , Vision Disorders/diagnosisABSTRACT
CONTEXT AND OBJECTIVE: In a cohort of 17 patients treated for nonfunctioning pituitary macroadenoma (NFMA), we observed alterations in polysomnographic sleep characteristics and actigraphic sleep-wake rhythmicity, and subjective fatigue, daytime somnolence, and low sleep quality. We aimed to confirm the actigraphic data in a larger scale cohort of NFMA patients, powered to address risk factors for altered rhythmicity, including the effects of hydrocortisone replacement. METHODS: Sleep-wake rhythmicity in treated NFMA patients was measured using actigraphy for 7 days, and subjective sleep quality and quality of life (QoL) with validated questionnaires. To assess the influence of hydrocortisone dependency, we additionally studied patients with Addison's disease (AD). The results were compared with matched healthy controls. RESULTS: We included 69 NFMA patients in long-term remission after trans-sphenoidal surgery on stable replacement therapy for hypopituitarism, 21 AD patients, and 58 controls. NFMA patients reported severely impaired QoL, sleep quality, and increased daytime sleepiness. The day-night dichotomy of activity was fragmented, with decreased daytime activity and a tendency for increased nighttime activity. Preoperative visual field defects (VFD) were associated with this fragmentation, and vasopressin deficiency with decreased sleep efficiency, independent of age, hypopituitarism, or radiotherapy. AD patients showed similar decreases in daytime functioning, but normal subjective and objective sleep, and no daytime sleepiness. CONCLUSION: NFMA patients suffer from altered sleep-wake rhythmicity. Hydrocortisone dependency may explain part of the decreased daytime functioning, but the independent influence of VFD and differences between AD and NFMA patients point towards a role for dysfunction of the adjacent suprachiasmatic nucleus (SCN).
Subject(s)
Pituitary Neoplasms/physiopathology , Sleep Disorders, Circadian Rhythm/physiopathology , Sleep , Wakefulness , Actigraphy , Addison Disease/complications , Addison Disease/physiopathology , Addison Disease/psychology , Adolescent , Adult , Aged , Cohort Studies , Cross-Sectional Studies , Female , Hormone Replacement Therapy , Humans , Hydrocortisone/therapeutic use , Hypopituitarism/etiology , Male , Middle Aged , Pituitary Neoplasms/complications , Pituitary Neoplasms/psychology , Quality of Life , Sleep Disorders, Circadian Rhythm/etiology , Sleep Disorders, Circadian Rhythm/psychology , Surveys and Questionnaires , Visual Field Tests , Young AdultABSTRACT
Cerebellar haemorrhage is an unusual complication of supratentorial neurosurgery. Several causative pre-operative factors and medical risk factors may predispose patients to cerebellar haemorrhage, however its etiology remains still unclear. Only two case reports have previously described the occurrence of cerebellar haemorrhage after subdural haematoma evacuation by burr-hole trepanation. We present two patients with this rare postoperative complication of minor supratentorial neurosurgery and possible underlying pathophysiological mechanisms are discussed. Our two cases support the post- rather than per-operative pathogenetic hypothesis. Although the complication is associated with a significant morbidity and mortality, most cases follow a benign course.
Subject(s)
Brain Hemorrhage, Traumatic/etiology , Brain Hemorrhage, Traumatic/pathology , Hematoma, Subdural, Chronic/surgery , Neurosurgical Procedures/adverse effects , Postoperative Complications/etiology , Postoperative Complications/pathology , Aged , Basilar Artery/injuries , Basilar Artery/pathology , Basilar Artery/physiopathology , Brain Hemorrhage, Traumatic/physiopathology , Cerebellum/blood supply , Cerebellum/pathology , Cerebellum/physiopathology , Cerebral Angiography , Craniotomy/adverse effects , Female , Humans , Intracranial Hypotension/complications , Intracranial Hypotension/pathology , Intracranial Hypotension/physiopathology , Magnetic Resonance Imaging , Male , Middle Aged , Postoperative Complications/physiopathology , Suction/adverse effects , Therapeutic Irrigation/adverse effects , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
UNLABELLED: As the value of grading of ependymomas is currently debated we studied the expression of proliferation- and apoptosis-related proteins in these tumors as these mechanisms both are suggested to be important in tumor growth. We characterized the immunohistochemical expression of p53, Mdm2, Bcl-2, and Bax in 51 intracranial ependymomas. We also assessed the apoptosis- and proliferation-index, measured by MIB-1, PCNA-immunohistochemistry, and analyzed the clinical parameters. Of all used antibodies, the correlation with survival and the correlation among ordered categories was assessed. None of the analyzed immunohistochemical variables were significantly correlated with tumor grade. On the other hand, PCNA, MIB-1, and p53 were significantly related to the survival of the patient. In multivariate analysis, p53 was the only independent predictive variable (p = 0.0132). CONCLUSION: The strongest predictors of survival in univariate analysis were the expression of PCNA, MIB-1 and p53. In multivariate analysis a p53 expression > 1% showed to be significantly related with a worse survival. The predicting value of p53 expression has to be confirmed by others before solid conclusions can be made. Apoptosis seems not to be an important mechanism in tumor growth in ependymomas. The expression of Mdm2, Bcl-2, and Bax were not related to survival.
